99% up by HPLC Carf...

99% up by HPLC Carfilzomib 868540-17-4

99% up by HPLC Carfilzomib 868540-17-4

Min.Order / FOB Price:Get Latest Price

0 Metric Ton

Negotiable

  • Min.Order :0 Metric Ton
  • Purity: 99% up by HPLC

Keywords

Carfilzomib Carfilzomib powder 868540-17-4

Quick Details

  • Appearance:
  • Application:API
  • PackAge:
  • ProductionCapacity:|Metric Ton|Day
  • Storage:
  • Transportation:

Superiority:

Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial since 1987
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different t

Details:

Product name

Carfilzomib

CAS No.

868540-17-4

Molecular Formula

C40H57N5O7

Molecular Weight

719.922

Molecular Structure

Quality Standard

98% up by HPLC

Appearance

White powder

 

COA of Carfilzomib

ITEM

SPECIFICATION

RESULTS

Appearance

White powder

Complies

Identification

IR, UF, HPLC. In comparison with Carfilzomib RS

Complies

Melting point(the Range of temperature≤4 )

230 

230 

Solubility

slightly soluble in water and in alchohol, freely soluble in acetic acid and in methanol

Complies

Heavy metal

0.001% - 0.002%

Complies

Loss on Drying

≤1.0%

0.23%

Residue on ignition

≤1.0%

0.08%

Residual organic solvents

Ranged I and II toxic class

Complies

Total impurities

≤1.0%

0.54%

Assay (by HPLC)

≥ 98.0%

98.96%

Conclusion

The results conforms with enterprise standard.

Studies have shown that lenalidomide combined with dexamethasone plus carfilzomib has unprecedented efficacy in the treatment of relapsed multiple myeloma. The three-drug combination therapy for patients with first relapsed multiple myeloma has a progression-free survival of more than two years, which confirms the efficacy of the three-drug combination. Although the interim data analysis of this trial did not yield median overall survival in either group, the addition of carfilzomib trended toward longer overall survival (73.3% in the added carfilzomib group and 65% in the control group). ), this test result did not exceed the statistical range set by the statistician at the beginning of the experiment. More importantly, the addition of carfilzomib did not significantly increase toxicity, and the quality of life score was also higher than that of the control group. Another important information brought by this trial is that the total effective rate of the three-drug combination is significantly higher than that of the two-drug combination, 87.4% and 66.9% in the two groups, respectively; the complete remission rate of the three-drug combination is more than 3 times higher, and the two Groups were 31.8% and 9.4%, respectively. By adding carfilzomib to the gold standard for the treatment of multiple myeloma, unprecedented duration of response was seen without increased toxicity, which holds great promise for relapsed and high-dose preconditioning patients. These results may establish 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View